Richard Finn

Richard Finn was the principal investigator of the IMbrave150 phase III trial demonstrating that atezolizumab plus bevacizumab significantly improved overall survival compared to sorafenib, establishing a new first-line standard of care for advanced HCC. He has contributed to multiple other landmark trials in HCC systemic therapy and has been involved in CDK4/6 inhibitor development in other cancers. His translational research investigates biomarkers predicting immunotherapy response in liver cancer. He is a leading voice in HCC clinical research and serves on multiple guideline panels.